JPWO2016120369A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2016120369A5 JPWO2016120369A5 JP2017540788A JP2017540788A JPWO2016120369A5 JP WO2016120369 A5 JPWO2016120369 A5 JP WO2016120369A5 JP 2017540788 A JP2017540788 A JP 2017540788A JP 2017540788 A JP2017540788 A JP 2017540788A JP WO2016120369 A5 JPWO2016120369 A5 JP WO2016120369A5
- Authority
- JP
- Japan
- Prior art keywords
- cxcr4
- composition according
- antagonists
- release
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YIQPUIGJQJDJOS-UHFFFAOYSA-N Plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229960002169 Plerixafor Drugs 0.000 claims description 5
- 230000003042 antagnostic Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940121384 CXC chemokine receptor type 4 (CXCR4) antagonists Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 4
- -1 phenylenebis (methylene) Chemical class 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- PTUYNGRETVWEER-UHFFFAOYSA-N 7-[[4-(4,7,10,17-tetrazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-7-ylmethyl)phenyl]methyl]-4,7,10,17-tetrazabicyclo[11.3.1]heptadeca-1(17),13,15-triene;octahydrobromide Chemical compound [Br-].[Br-].[Br-].[Br-].[Br-].[Br-].[Br-].[Br-].C1C[NH2+]CCC([NH+]=2)=CC=CC=2CC[NH2+]CC[NH+]1CC(C=C1)=CC=C1C[NH+](CC[NH2+]CC1)CC[NH2+]CCC2=CC=CC1=[NH+]2 PTUYNGRETVWEER-UHFFFAOYSA-N 0.000 claims 1
- VUYRSKROGTWHDC-HZGLMRDYSA-N CTCE 9908 Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(N)=O)C1=CC=C(O)C=C1 VUYRSKROGTWHDC-HZGLMRDYSA-N 0.000 claims 1
- 108010053045 CTCE-9908 Proteins 0.000 claims 1
- 101710003734 CXCR4 Proteins 0.000 claims 1
- 102100002212 CXCR4 Human genes 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N Cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000003182 bronchodilatating Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 108091005593 modified peptides Proteins 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 230000000541 pulsatile Effects 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 2
- 229940074923 Mozobil Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
Description
ビシクラムは、とりわけ、国際公開第WO00/56729号に記載されている。ビシクラム分子の中では、プレリキサフォル（AMD3100としても指定されており商用名MozobilでGenzyme Corporationにより市販され、とりわけ米国特許第5,583,131号およびUy et al., Expert Opin Biol Ther. 2008 Nov;8（11）:1797-804. doi: 10.1517/14712598.8.11.1797に記載されている）のようなパラ－キシリル－エンジアミンベースの化合物を挙げることができる。プレリキサフォルの誘導体または構造的に修飾された化合物もまた、本発明の組成物におけるアンタゴニストとして使用され得る。かかる誘導体は、芳香族結合ポリアミン大環状化合物、例えばとりわけ国際公開第WO93/12096号および米国特許5,583,131号に記載されているプレリキサフォルのテトラフルオロ誘導体であり得る。
Claims (8)
- ケモカイン受容体ＣＸＣＲ４に対する、少なくとも１種のアンタゴニストの治療有効量を含む、ＡＥＣＯＰＤを予防および／または処置する方法における使用のための組成物であって、ＡＥＣＯＰＤが、気管支および／または気管支周囲線維症によって特徴付けられ、アンタゴニストが、インドールベースのＣＸＣＲ４アンタゴニスト、ビシクラムＣＸＣＲ４アンタゴニスト、シクラム模倣薬ＣＸＣＲ４アンタゴニスト、グアニジンベースのＣＸＣＲ４アンタゴニスト、テトラヒドロキノリンベースのＣＸＣＲ４アンタゴニスト、パラ－キシリル－エンジアミンベースのＣＸＣＲ４アンタゴニスト、１，４－フェニレンビス（メチレン）ＣＸＣＲ４アンタゴニスト、ピリミジンベースのＣＸＣＲ４アンタゴニスト、および、修飾ペプチドＣＸＣＲ４アンタゴニストから選択される、前記組成物。
- アンタゴニストが、プレリキサフォル（AMD3100）、またはプレリキサフォルのテトラフルオロ誘導体、ブリキサフォア(TG-0054)、JM1657、AMD3329、AMD3465、AMD070、MSX-122、CTCE-9908、WZ811、およびBKT-140から選択される小分子である、請求項１に記載の組成物。
- ＣＸＣＲ４アンタゴニストがプレリキサフォルである、請求項１または２に記載の組成物。
- 請求項１～３のいずれか一項に記載の組成物および薬学的に許容し得るビヒクルを含む、ＡＥＣＯＰＤを予防および／または処置する方法における使用のための医薬組成物。
- 気管支拡張薬、コルチコイド、および／またはホスホジエステラーゼ阻害剤をさらに含む、請求項４に記載の医薬組成物。
- 該組成物が、経口、口腔または舌下に投与され、即時放出、遅延放出、調節放出、持続放出、二重放出、制御放出または拍動送達用途のための、香味剤または着色剤を含有し得る、錠剤、カプセル（ソフトゲルカプセルを含む）、多粒子剤、ゲル、フィルム、エリキシル、溶液または懸濁液の形態である、請求項４または５に記載の医薬組成物。
- 該組成物が、吸入により投与され、乾燥粉末吸入器、または、圧力容器、ポンプ、スプレーもしくはネブライザーからのエアロゾルスプレー提示の形態である、請求項６に記載の医薬組成物。
- 請求項４～７のいずれか一項に記載の医薬組成物の１以上の用量を含む、ＡＥＣＯＰＤを予防および／または処置する方法における使用のためのキットまたは医薬パッケージ。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152886.6 | 2015-01-28 | ||
| EP15152886.6A EP3050574B1 (en) | 2015-01-28 | 2015-01-28 | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
| PCT/EP2016/051771 WO2016120369A1 (en) | 2015-01-28 | 2016-01-28 | New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505187A JP2018505187A (ja) | 2018-02-22 |
| JPWO2016120369A5 true JPWO2016120369A5 (ja) | 2022-05-30 |
| JP7127988B2 JP7127988B2 (ja) | 2022-08-30 |
Family
ID=52434596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540788A Active JP7127988B2 (ja) | 2015-01-28 | 2016-01-28 | 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10813911B2 (ja) |
| EP (2) | EP3613435A1 (ja) |
| JP (1) | JP7127988B2 (ja) |
| CN (1) | CN107405405B (ja) |
| AU (1) | AU2016212067B2 (ja) |
| BR (1) | BR112017016347A2 (ja) |
| CA (1) | CA2972319C (ja) |
| DK (1) | DK3050574T3 (ja) |
| EA (1) | EA201791689A1 (ja) |
| ES (1) | ES2764840T3 (ja) |
| IL (1) | IL253688B2 (ja) |
| WO (1) | WO2016120369A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017127810A1 (en) * | 2016-01-22 | 2017-07-27 | Indiana University Research & Technology Corporation | Methods for repairing lung tissue |
| US20190233524A1 (en) * | 2017-09-18 | 2019-08-01 | Tcm Biotech International Corp. | Therapeutic combination and method for treating cancer |
| EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| DE69434878T3 (de) | 1993-09-14 | 2014-07-17 | Imperial Innovations Ltd. | Eotaxin = eosinophil chemotaktisches cytokin |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6806061B1 (en) | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| JP4176148B2 (ja) | 1996-05-20 | 2008-11-05 | 帝人ファーマ株式会社 | ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用 |
| CA2278309A1 (en) | 1997-01-21 | 1998-07-23 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| EP0966443B1 (en) | 1997-02-26 | 2009-01-28 | Pfizer Inc. | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor |
| US6207155B1 (en) | 1997-05-07 | 2001-03-27 | Schering Corporation | Method of eosinophil depletion with antibody to CCR 3 receptor |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1045901B1 (en) | 1998-01-15 | 2004-11-03 | King'S College London | Ribozymal nucleic acids cleaving ccr5 or cxcr4 |
| AU760208B2 (en) | 1998-02-27 | 2003-05-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | G protein-coupled receptor antagonists |
| US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
| CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| AU1408300A (en) | 1998-11-24 | 2000-06-13 | Hisamitsu Pharmaceutical Co. Inc. | Hiv infection inhibitors |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| AU2002251913A1 (en) | 2001-02-02 | 2002-08-19 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
| US20050124569A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
| EP2298717B1 (en) | 2001-11-30 | 2015-10-28 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
| TW200305395A (en) | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| BR0312358A (pt) | 2002-07-02 | 2005-04-05 | Hoffmann La Roche | Derivados de pirimidina 2,5-substituìda como antagonistas ix de receptor de ccr-3 |
| US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| EP1599472A1 (en) | 2003-02-27 | 2005-11-30 | F. Hoffmann-La Roche Ag | Ccr-3 receptor antagonists |
| US20050069955A1 (en) | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| AR046594A1 (es) | 2003-10-16 | 2005-12-14 | Applied Research Systems | Usos terapeuticos de variantes de quemoquina |
| CN1922197A (zh) | 2004-02-20 | 2007-02-28 | 吉尼西斯研究及发展有限公司 | 用于治疗IgE介导的失调的RNA干涉分子的靶向递送 |
| EP1753758B1 (en) | 2004-05-26 | 2009-03-11 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| EA200700757A1 (ru) | 2004-09-28 | 2007-10-26 | Янссен Фармацевтика Н.В. | Замещённые дипиперидиновые антагонисты ccr2 |
| AP2007004095A0 (en) | 2005-01-07 | 2007-08-31 | Univ Emory | Cxcr4 antagonists for the treatment of hiv infection |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| PE20061444A1 (es) | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
| GB0517966D0 (en) | 2005-09-02 | 2005-10-12 | Novartis Ag | Organic compounds |
| HUP0500877A2 (en) | 2005-09-22 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates |
| US20090297502A1 (en) | 2006-06-15 | 2009-12-03 | Li Li | Ccr2 antagonists for chronic organ transplantation rejection |
| ATE537166T1 (de) | 2006-10-27 | 2011-12-15 | Boehringer Ingelheim Int | Piperidylpropanthiole als ccr3-modulatoren |
| BRPI0812134A2 (pt) | 2007-05-30 | 2014-11-18 | Lilly Co Eli | Anatagonistas de cxcr4 de peptídio cíclico |
| WO2009009740A1 (en) | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
| US8440199B2 (en) * | 2007-12-12 | 2013-05-14 | Imperial Innovations Limited | Methods for mobilizing mesenchymal stem cells in a patient |
| HUP0800478A2 (en) | 2008-07-31 | 2010-03-01 | Sanofi Aventis | Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands |
| WO2010069979A1 (en) | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| CN103724328B (zh) | 2008-12-19 | 2015-10-14 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| KR20120006544A (ko) | 2009-04-17 | 2012-01-18 | 얀센 파마슈티카 엔.브이. | Ｃｃｒ2의 4-아제티디닐-1-페닐-사이클로헥산 길항제 |
| US8471004B2 (en) | 2009-10-07 | 2013-06-25 | Hoffman-La Roche Inc. | Bicyclic compounds |
| US8445674B2 (en) | 2009-10-21 | 2013-05-21 | Hoffmann-La Roche Inc | Heterocyclyl compounds |
| JP5356323B2 (ja) * | 2010-07-01 | 2013-12-04 | 富士化学工業株式会社 | 新規な非晶質ボセンタン及びその製造方法 |
| MX2013003954A (es) * | 2010-10-11 | 2013-08-01 | Axikin Pharmaceuticals Inc | Sales de arilsulfonamida antagonistas de ccr3. |
| US8921559B2 (en) | 2010-12-01 | 2014-12-30 | Janssen Pharmaceutica Nv | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 |
| EP2685824A4 (en) | 2011-03-17 | 2014-09-10 | Merck Sharp & Dohme | INDOLE DERIVATIVES USEFUL AS CCR2ANTAGONISTS |
| WO2012138880A2 (en) | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| US20150164874A1 (en) * | 2011-05-25 | 2015-06-18 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| DK2723360T3 (en) | 2011-06-27 | 2017-08-28 | Université Pierre Et Marie Curie (Paris 6) | CCR2 antagonist peptides |
| US20140336159A1 (en) * | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| CA2852830A1 (en) * | 2011-10-18 | 2013-04-25 | Biocon Limited | Acid addition salts of bosentan |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| CN105377251A (zh) * | 2013-03-01 | 2016-03-02 | 马特医疗研究中心有限公司 | 动员剂及其用途 |
| WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
-
2015
- 2015-01-28 DK DK15152886.6T patent/DK3050574T3/da active
- 2015-01-28 ES ES15152886T patent/ES2764840T3/es active Active
- 2015-01-28 EP EP19197843.6A patent/EP3613435A1/en not_active Withdrawn
- 2015-01-28 EP EP15152886.6A patent/EP3050574B1/en active Active
-
2016
- 2016-01-28 CN CN201680008472.9A patent/CN107405405B/zh active Active
- 2016-01-28 US US15/547,099 patent/US10813911B2/en active Active
- 2016-01-28 CA CA2972319A patent/CA2972319C/en active Active
- 2016-01-28 WO PCT/EP2016/051771 patent/WO2016120369A1/en active Application Filing
- 2016-01-28 EA EA201791689A patent/EA201791689A1/ru unknown
- 2016-01-28 AU AU2016212067A patent/AU2016212067B2/en active Active
- 2016-01-28 JP JP2017540788A patent/JP7127988B2/ja active Active
- 2016-01-28 BR BR112017016347-0A patent/BR112017016347A2/pt not_active Application Discontinuation
-
2017
- 2017-07-27 IL IL253688A patent/IL253688B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019112434A (ja) | 定量吸入器を用いたトレプロスチニル投与 | |
| Beeh et al. | The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease | |
| US6458338B1 (en) | Amino acid stabilized medicinal aerosol formulations | |
| AU2012203343A1 (en) | Compositions comprising azelastine and methods of use thereof | |
| AU2001245190A1 (en) | A medicinal aerosol formulation | |
| CN110237260A (zh) | 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 | |
| ZA200600411B (en) | Methods of treating COPD and Pulmonary Hypertension | |
| AU2837401A (en) | Aerosol composition comprising formoterol | |
| HU227519B1 (en) | Synergic pharmaceutical composition containing combination of formoterol and budesonide | |
| JP2008512434A (ja) | ベータ擬似剤の異性体及び抗コリン作用剤を含む医薬組成物 | |
| JP2002538110A (ja) | 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ | |
| RU2019121646A (ru) | Способы и композиции для лечения легочной гипертензии и других заболеваний легких | |
| JP2006502160A (ja) | 水安定化エアゾル薬剤組成 | |
| CA3172665A1 (en) | Treprostinil for use in the treatment of intersitial lung disease | |
| NO334247B1 (no) | Medikament omfattende roflumilast i kombinasjon med formoterol | |
| JP2022520990A (ja) | 呼吸器疾患の治療の方法 | |
| JPWO2016120369A5 (ja) | ||
| TW202140013A (zh) | ５－胺基－２，３二氫－１，４－酞嗪二酮或其藥學上可接受的鹽用於吸入性治療肺疾病之應用、氣霧劑及其製造方法以及套件 | |
| PL211574B1 (pl) | Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego | |
| NO334148B1 (no) | Synergistisk kombinasjon omfattende roflumilast og (R,R)-formoterol | |
| JP2018058881A (ja) | 医薬組成物 | |
| AU2012201428B2 (en) | Compositions comprising azelastine and methods of use thereof | |
| WO2024098009A1 (en) | Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications | |
| SINHA et al. | Inhaled therapeutics in chronic obstructive pulmonary | |
| KR20230052903A (ko) | 흡입 투여를 위한 병용 요법 |